It Crushes Visceral Fat, But the Scale Barely Moves!

Physionic

May 28, 2026

Episode description

JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2

HEALTH AUTONOMY [COURSE]
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy

JOIN THE COMMUNITY
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2

EMAIL LIST
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6

HIRE ME FOR CONSULTING:
Consulting: https://bit.ly/3dmUl2H

Created with Biorender

0:00 - Introduction
1:15 - TH9507, by it’s Terminator Name
3:05 - Visceral Fat specific Exile
6:16 - HIV Specific or…?
8:07 - Safety (Higher IGF-1??)
9:20 - Not for Everyone, though

Reducing Visceral Fat through a Food: https://www.youtube.com/watch?v=0Er08-E2HnU&t=1s
The Best Peptide: https://www.youtube.com/watch?v=T9KJ8HGRmwM

References*
*Full Funding/Conflicts are provided in the free article (found in email list and Physionic Community Article Library)
[1] Kadowaki T, Nishida T, Ogawa W, Overvad M, Tobe K, Yamauchi T. Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial. Obes Res Clin Pract. 2025;19(2):146-153. doi:10.1016/j.orcp.2025.03.003

[Study 788] Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287.

[Study 789] Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.

[Study 790] Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490.

[Study 791] Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-1288. doi:10.1097/QAD.0b013e328347f3f1.

[Study 792] Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651. doi:10.1093/cid/cis251.

[Study 793] Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-4779. doi:10.1210/jc.2012-2794.

[Study 794] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8334.

[Study 795] Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019. Published online October 11, 2019. doi:10.1016/S2352-3018(19)30338-8.

[Study 796] Lake JE, La K, Erlandson KM, et al. Tesamorelin improves fat quality independent
of changes in fat quantity. AIDS. 2021;35(9):1395-1402. doi:10.1097/QAD.0000000000002897.

[Study 797] Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Effect of tesamorelin in people with HIV with and without dorsocervical fat: post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2023;7:e40. doi:10.1017/cts.2022.515.

[Study 798] Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. doi:10.1097/QAD.0000000000003965.

[Study 780] Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275

Please use the following link to submit your critique: https://bit.ly/PhysionicCritique

Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.

Mindsip insights from this episode:

Reduce visceral fat without affecting scale weight

Tesamorelin's impact is unique because it leads to a reduction in visceral fat, but your whole body weight on the scale doesn't budge.

#visceral-fat

Utilize Tesamorelin to target visceral fat reduction

A peptide called Tesamorelin (formerly TH9507) is believed to have an especially unique disappearing effect on visceral fat.

#peptides

#visceral-fat

Utilize tesamorelin to target visceral fat effectively

Tesamorelin mimics the GHRH hormone, which binds to the pituitary gland and increases growth hormone release, a hormone to which visceral fat is especially sensitive.

#visceral-fat

Acknowledge unknown long-term safety of Tesamorelin

The longest studies on Tesamorelin last for about a year, so there is no long-term data on potential concerns like cancer, which might arise from increased IGF-1.

#cancer

#risk

Consider tesamorelin for low growth hormone and visceral fat loss

Tesamorelin is likely the peptide of choice for people with chronically low growth hormone or for those who want to lose visceral fat but not more body weight, like 'TOFI' (Thin Outside, Fat Inside) individuals.

#peptides

#visceral-fat

Utilize tesamorelin to build lean mass without weight gain

The peptide has a unique lean mass effect, likely contributing to the lack of change in overall weight.

#muscle

#peptides

Boost lean mass by increasing IGF-1 with tesamorelin

Tesamorelin significantly increases IGF-1 (insulin-like growth factor 1), which is known to stimulate cell growth and likely causes the observed increase in lean mass.